Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours
- 22 August 2019
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 38 (3) , 899-908
Abstract
Adrenocortical carcinoma (ACC) is an aggressive endocrine cancer with few molecular predictors of malignancy and survival, especially in paediatric patients. Stathmin 1 (STMN1) regulates microtubule dynamics and has been involved in the malignant phenotype of cancer cells. Recently, it was reported that STMN1 is highly expressed in ACC patients, and STMN1 silencing reduces the clonogenicity and migration of ACC cell lines. However, the prognostic significance of STMN1 and its therapeutic potential remain undefined in ACC. In the present study, STMN1 mRNA levels were significantly higher (p < 0.05) in ACC patients, especially in an advanced stage, and correlated with BUB1B and PINK1 expression, the prognostic-related genes in ACC. In paediatric tumours, high STMN1 expression was observed in both adrenocortical carcinoma and adrenocortical adenoma patients. Among the adult malignant tumours, STMN1 level was an independent predictor of survival outcomes (overall survival: hazard ratio = 6.08, p = 0.002; disease-free survival: hazard ratio = 4.65, p < 0.0001). Paclitaxel, a microtubule-stabilizing drug, reduces the activation of STMN1 and significantly decreases cell migration and invasion in ACC cell lines and ACC cells from secondary cell culture (all p < 0.0001). In summary, STMN1 expression may be of great value to clinical and pathological findings in therapeutic trials and deserves future studies in ACC.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2015/014199-9, 2017/24993-0, 2016/12381-7, 2016/17285-6)
This publication has 31 references indexed in Scilit:
- Apoptosis regulation in adrenocortical carcinomaEndocrine Connections, 2019
- MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinomaEuropean Journal of Endocrinology, 2018
- Comprehensive Pan-Genomic Characterization of Adrenocortical CarcinomaCancer Cell, 2016
- Stathmin 1 in normal and malignant hematopoiesisBMB Reports, 2014
- Integrated genomic characterization of adrenocortical carcinomaNature Genetics, 2014
- Adrenocortical CarcinomaEndocrine Reviews, 2013
- Management of adjuvant mitotane therapy following resection of adrenal cancerEndocrine, 2012
- Stathmin: a protein with many tasks. New biomarker and potential target in cancerExpert Opinion on Therapeutic Targets, 2011
- Gene Expression Profiling of Childhood Adrenocortical TumorsCancer Research, 2007
- Adrenal Cortical Neoplasms in the Pediatric PopulationAmerican Journal of Surgical Pathology, 2003